Leukocytoclastic vasculitis (LCV), also known as small-vessel cutaneous vasculitis, is rarely seen in the setting of staphylococcal infection without bacteremia. Here, we present a case of LCV in a 61-year-old male with chronic staphylococcal osteomyelitis without any evidence of bacteremia. The rash resolved with the treatment of osteomyelitis. As seen in this case, local infection should be considered in the differential diagnosis of LCV even when there is no evidence of bacteremia.
Hydralazine is a commonly prescribed medication which is used in the treatment of hypertension. While it is generally considered to be a safe and effective treatment, in rare cases it can cause a serious side effect known as hydralazine-induced vasculitis. Here we discuss this rare presentation in the form of a case report in a 67-year-old female with a past medical history of chronic obstructive pulmonary disease (COPD), congestive heart failure, hypertension, hyperlipidemia, left renal artery stenosis status post stenting who presented in the nephrology office for evaluation of recent worsening kidney function, and on further evaluation was found to have hematuria and proteinuria in the urine analysis. On further workup, she was noted to have severely elevated myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) titers with renal biopsy revealed very focal crescentic glomerulonephritis, an increased number of occlusive red blood cell cast with acute tubular necrosis. Mild interstitial fibrosis of <20% was seen and a diagnosis of drug-induced vasculitis from hydralazine was made.
Introduction: It remains unclear what percentage of abstracts proceed to manuscript publication and the characteristics that predict successful publication. This study aimed to determine factors associated with successful peer-reviewed publications following oral presentation at the American Society of Hematology (ASH) annual meeting. Methods: All oral abstract presentations (n=621) in the hematological malignancy category from 2016 ASH annual meeting were included in the study. Abstract publication was confirmed by searching for the publicly listed abstract on PubMed by title, first, and last author names, and institutional matching. We recorded time to online publication, US versus foreign journal publication, and journal impact factor by 3.5 years from 2016 ASH annual meeting. Abstracts characteristics that were analyzed also included number of authors, gender of first author, gender of last author, and single vs multi-institution studies. Gender of the first and last author was confirmed by looking at their biography details on their institutional website. Descriptive analysis was performed and an association between presenter's or last author's gender and publication matrix was analyzed using Chi-square tests. Results: Of the 621 abstracts, 350 (56%) were published in full text by three and a half years since the 2016 ASH annual meeting. The abstracts' average time to journal publication was 17.46 months (SD +/- 11.32) (Table 1). Of the published articles, 64% (223/350) were published in U.S. journals; mean impact factor for all publications was 14.46 (SD+/- 11.47).The median number of authors for published and unpublished abstracts were similar. Females presented 37% (228/621) of the abstracts and 35% (123/350) of the journal publications had female first author and 22% (77/350) had female last author. A total of 53.9% (123/228) abstracts presented by a female author were published versus 57.7% (227/393) abstracts presented by a male author (p=<0.001). Males were more often involved in multi-institutional trials (p=0.045) and were more likely to have senior authorship (p=0.005). There was no correlation between the gender of the first author to journal impact factor (p=0.109) or time to publication (p=0.091). Conclusion: More than half of the oral abstracts were successfully published regardless of gender and number of authors. The rate of successful publication is higher for male authors even though there was no correlation between the gender of the first author to journal impact factor or time to publication. Our study highlights gender disparity in senior authorship, however this difference is not as wide in first authorship. Disclosures Jamshed: Takeda, Amgen and Celgene: Honoraria.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.